Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.47 |
| ▸ | CLK1 | P49759 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.46 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.46 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3138823 | 0.86 | SLC6A4 (0.58) | FFAR4SMN1; SMN2ALDH1A1HPGDSLC6A4 | |
| SCHEMBL4300383 | 0.85 | SMN1; SMN2 (0.52) | SMN1; SMN2ALDH1A1HPGDSLC6A4SLC6A3 | |
| SCHEMBL27709578 | 0.85 | NPC1 (0.51) | FFAR4SMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL15743618 | 0.84 | FFAR4 (0.51) | FFAR4SMN1; SMN2ALDH1A1HPGDSLC6A4 | |
| SCHEMBL1020142 | 0.83 | SMN1; SMN2 (0.49) | SMN1; SMN2ALDH1A1HPGDKDM4ENPC1 | |
| SCHEMBL30134039 | 0.83 | SMN1; SMN2 (0.49) | SMN1; SMN2ALDH1A1HPGDKDM4ENPC1 | |
| SCHEMBL927338 | 0.83 | ALDH1A1 (0.62) | FFAR4SMN1; SMN2ALDH1A1HPGDKDM4E | |
| SCHEMBL30675620 | 0.83 | ALDH1A1 (0.62) | FFAR4SMN1; SMN2ALDH1A1HPGDKDM4E | |
| SCHEMBL20231757 | 0.83 | FFAR4 (0.50) | FFAR4SMN1; SMN2ALDH1A1HPGDSLC6A4 | |
| SCHEMBL2532235 | 0.83 | TSHR (0.54) | SMN1; SMN2NPC1RAB9AGAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 200 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | UNIV YALE (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4168399-B1 | COMPOUNDS AND THEIR USES AS MIF INHIBITORS | NANJING IMMUNOPHAGE BIOMEDICAL CO LTD (CN) | 2026-04-01 | — | — | EP | disclosed |
| US-20260069559-A1 | COMBINATIONS OF RXFP1 MODULATORS AND SGLT2 INHIBITORS | ASTRAZENECA AB (SE) | 2026-03-12 | — | — | US | disclosed |
| US-20260069558-A1 | RXFP1 MODULATORS FOR TREATING RESISTANT HYPERTENSION OR HEART FAILURE WITH PULMONARY HYPERTENSION | ASTRAZENECA AB (SE) | 2026-03-12 | — | — | US | disclosed |
| US-20250312350-A1 | INHIBITORS OF RLIP76 | AVESTA76 THERAPEUTICS, INC. (US) | 2025-10-09 | — | — | US | disclosed |
| EP-4536206-A1 | RXFP1 MODULATORS FOR TREATING RESISTANT HYPERTENSION OR HEART FAILURE WITH PULMONARY HYPERTENSION | Astrazeneca AB (SE) | 2025-04-16 | — | — | EP | disclosed |
| EP-4536207-A1 | COMBINATIONS OF RXFP1 MODULATORS AND SGLT2 INHIBITORS | Astrazeneca AB (SE) | 2025-04-16 | — | — | EP | disclosed |
| CN-119630638-A | Solid forms of RXFP1 modulators | 阿斯利康(瑞典)有限公司 | 2025-03-14 | — | — | CN | disclosed |
| CN-119486724-A | RXFP1 modulators for the treatment of refractory hypertension or heart failure combined with pulmonary hypertension | 阿斯利康(瑞典)有限公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-119325376-A | Combination of RXFP1 modulator and SGLT2 inhibitor | 阿斯利康(瑞典)有限公司 | 2025-01-17 | — | — | CN | disclosed |
| EP-1622912-A2 | 2-ALKYNYL-AND 2-ALKENYL-PYRAZOLO- [4,3-E] -1,2,4-TRIAZOLO- [1,5-C] -PYRIMIDINE ADENOSINE A sb 2A /sb RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2006-02-08 | — | — | EP | disclosed |
| US-20050222164-A1 | extra pyramidal syndrome, dystonia, restless leg syndrome or periodic limb movement in sleep; central nervous system diosrders; neurodegenerative diseases; attention deficit disorders; sedatives, antixiolytic and antiepileptic agents | MERCK SHARP & DOHME LLC | 2005-10-06 | — | — | US | disclosed |
| WO-2005080359-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS GLUCOKINAE ACTIVATING AGENTS | ASTRAZENECA AB (SE) | 2005-09-01 | — | — | WO | disclosed |
| US-6897217-B2 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION (US) | 2005-05-24 | — | — | US | disclosed |
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION | 2004-11-04 | — | — | US | disclosed |
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION | 2004-11-04 | — | — | US | disclosed |
| WO-2004094431-A2 | 2-ALKYNYL-AND 2-ALKENYL-PYRAZOLO-[4,3-E]-1,2,4-TRIAZOLO-[1,5-C]-PYRIMIDINE ADENOSINE A2A RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2004-11-04 | — | — | WO | disclosed |
| US-6194461-B1 | USEFUL AS MEDICAMENT FOR TREATING RETINAL DEGENERATIVE DISORDERS; ALPHA-(2,4-DIFLUOROPHENYL)-N-T-BUTYLNITRONE, AND CORRESPONDING AMINES WHICH WOULD BE CONVERTED IN VIVO TO THE NITRONE, FOR EXAMPLE | SUMITOMO PHARMACEUTICALS CO., LTD. (JP) | 2001-02-27 | — | — | US | disclosed |
| CN-1238759-A | Nitrone derivatives | SUMITOMO PHARMA (JP) | 1999-12-15 | — | — | CN | disclosed |
| EP-0945426-A1 | NITRONE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1999-09-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260069559-A1 | COMBINATIONS OF RXFP1 MODULATORS AND SGLT2 INHIBITORS | RXFP1, RXFP2, RXFP4 | FFAR4 313/4885SMN1; SMN2 2694/4885ALDH1A1 2557/4885 |
| US-20050222164-A1 | extra pyramidal syndrome, dystonia, restless leg syndrome or periodic limb movement in sleep; central nervous system diosrders; neurodegenerative diseases; attention deficit disorders; sedatives, antixiolytic and antiepileptic agents | DRD3, DRD2, SLC6A3 | FFAR4 1931/4885SMN1; SMN2 680/4885ALDH1A1 1507/4885 |
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | ADORA2A, ADORA3, ADORA1 | FFAR4 201/4885SMN1; SMN2 837/4885ALDH1A1 591/4885 |
| US-20250312350-A1 | INHIBITORS OF RLIP76 | BCCIP, LRRFIP1, TIPARP | FFAR4 4081/4885SMN1; SMN2 4465/4885ALDH1A1 4012/4885 |
| US-20260069558-A1 | RXFP1 MODULATORS FOR TREATING RESISTANT HYPERTENSION OR HEART FAILURE WITH PULMONARY HYPERTENSION | RXFP1, RXFP3, RXFP2 | FFAR4 1006/4885SMN1; SMN2 2535/4885ALDH1A1 2913/4885 |
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, VHL, ADRM1 | FFAR4 3630/4885SMN1; SMN2 2142/4885ALDH1A1 2777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.